JP2021501601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501601A5 JP2021501601A5 JP2020542053A JP2020542053A JP2021501601A5 JP 2021501601 A5 JP2021501601 A5 JP 2021501601A5 JP 2020542053 A JP2020542053 A JP 2020542053A JP 2020542053 A JP2020542053 A JP 2020542053A JP 2021501601 A5 JP2021501601 A5 JP 2021501601A5
- Authority
- JP
- Japan
- Prior art keywords
- cornulin
- protein
- seq
- loss
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100032202 Cornulin Human genes 0.000 claims 43
- 101710148705 Cornulin Proteins 0.000 claims 43
- 150000007523 nucleic acids Chemical group 0.000 claims 27
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 14
- 235000018417 cysteine Nutrition 0.000 claims 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 208000017520 skin disease Diseases 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 239000002299 complementary DNA Substances 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 102000007982 Phosphoproteins Human genes 0.000 claims 7
- 108010089430 Phosphoproteins Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 235000018102 proteins Nutrition 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229960003735 brodalumab Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 231100000221 frame shift mutation induction Toxicity 0.000 claims 1
- 230000037433 frameshift Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229960005435 ixekizumab Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
- -1 solarene Chemical compound 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572958P | 2017-10-16 | 2017-10-16 | |
| US62/572,958 | 2017-10-16 | ||
| PCT/US2018/055995 WO2019079238A1 (en) | 2017-10-16 | 2018-10-16 | CORNULIN VARIANTS (CRNN) AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501601A JP2021501601A (ja) | 2021-01-21 |
| JP2021501601A5 true JP2021501601A5 (enExample) | 2021-11-25 |
Family
ID=64110144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542053A Withdrawn JP2021501601A (ja) | 2017-10-16 | 2018-10-16 | コルヌリン（ｃｒｎｎ）バリアント及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11098363B2 (enExample) |
| EP (1) | EP3697807A1 (enExample) |
| JP (1) | JP2021501601A (enExample) |
| KR (1) | KR20200065045A (enExample) |
| CN (1) | CN111315765A (enExample) |
| AU (1) | AU2018352234A1 (enExample) |
| CA (1) | CA3079167A1 (enExample) |
| IL (1) | IL273671A (enExample) |
| MX (1) | MX2020003565A (enExample) |
| RU (1) | RU2020115869A (enExample) |
| SG (1) | SG11202002822XA (enExample) |
| WO (1) | WO2019079238A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020358847A1 (en) * | 2019-10-03 | 2022-04-21 | Regeneron Pharmaceuticals, Inc. | A Crnn loss of function rodent model |
| KR102742136B1 (ko) | 2020-05-29 | 2024-12-11 | 주식회사 엘지에너지솔루션 | 양극 스크랩을 이용한 활물질 재사용 방법 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| CA2164288A1 (en) | 1993-06-04 | 1994-12-22 | Barbara Ensoli | Method for treating kaposi's sarcoma with antisense oligonucleotides |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| AU3222795A (en) | 1994-08-09 | 1996-03-07 | Ciba-Geigy Ag | Antitumor antisense oligonucleotides |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| AU7286696A (en) | 1995-10-13 | 1997-05-07 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| AU708096B2 (en) | 1995-11-21 | 1999-07-29 | Icn Pharmaceuticals, Inc. | Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor |
| JP2000506384A (ja) | 1996-02-15 | 2000-05-30 | ナショナル インスティチューツ オブ ヘルス | ＲＮａｓｅ Ｌ アクチベーター及びＲＳＶ感染の治療に有効なアンチセンスオリゴヌクレオチド |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
| US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
| JP2002502605A (ja) * | 1998-02-09 | 2002-01-29 | ジェンセット | 分泌タンパク質をコードするｃＤＮＡ |
| GB9805918D0 (en) * | 1998-03-19 | 1998-05-13 | Nycomed Amersham Plc | Sequencing by hybridisation |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| WO2013176772A1 (en) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| ES2713243T3 (es) | 2012-12-06 | 2019-05-20 | Sigma Aldrich Co Llc | Modificación y regulación del genoma basada en CRISPR |
| CN106620694B (zh) | 2016-12-30 | 2019-12-27 | 西安交通大学 | Cornulin作为靶点在制备防治银屑病的药物中的应用 |
-
2018
- 2018-10-16 AU AU2018352234A patent/AU2018352234A1/en not_active Withdrawn
- 2018-10-16 CA CA3079167A patent/CA3079167A1/en active Pending
- 2018-10-16 RU RU2020115869A patent/RU2020115869A/ru unknown
- 2018-10-16 KR KR1020207013082A patent/KR20200065045A/ko not_active Withdrawn
- 2018-10-16 MX MX2020003565A patent/MX2020003565A/es unknown
- 2018-10-16 JP JP2020542053A patent/JP2021501601A/ja not_active Withdrawn
- 2018-10-16 US US16/161,331 patent/US11098363B2/en active Active
- 2018-10-16 SG SG11202002822XA patent/SG11202002822XA/en unknown
- 2018-10-16 CN CN201880072216.5A patent/CN111315765A/zh not_active Withdrawn
- 2018-10-16 EP EP18797344.1A patent/EP3697807A1/en not_active Withdrawn
- 2018-10-16 WO PCT/US2018/055995 patent/WO2019079238A1/en not_active Ceased
-
2020
- 2020-03-29 IL IL273671A patent/IL273671A/en unknown
-
2021
- 2021-07-19 US US17/378,900 patent/US20220017964A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy | |
| JP2016516735A5 (enExample) | ||
| JP2014510533A (ja) | サイクリン依存性キナーゼ阻害剤に関連するマーカー | |
| JP2016511406A5 (enExample) | ||
| JP2012512389A5 (enExample) | ||
| Tremlett et al. | Serum proteomics in multiple sclerosis disease progression | |
| EP3347712B1 (en) | Methods of identifying drug-modulated polypeptide targets for degradation | |
| CN109313182B (zh) | 鱼变态反应的抗原 | |
| Meng et al. | Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions | |
| JP2021501601A5 (enExample) | ||
| JPWO2006073195A1 (ja) | 糖尿病の予知・診断方法および糖尿病予知・診断用キット | |
| CN107312861A (zh) | 一种b‑all患者预后风险评估标记物 | |
| JP2015502137A5 (enExample) | ||
| Etokebe et al. | Association of variable number of tandem repeats in the coding region of the FAM46A gene, FAM46A rs11040 SNP and BAG6 rs3117582 SNP with susceptibility to tuberculosis | |
| CN102186976A (zh) | 修饰型生物素结合蛋白 | |
| CN107190071B (zh) | 一种用于检测RhD变异表型的SNP标记 | |
| KR101547307B1 (ko) | 뇌전증 진단용 바이오마커 | |
| CN104232650B (zh) | 特发性基底节钙化新的致病基因及其编码蛋白质和应用 | |
| JP2017143745A (ja) | 冠動脈イベント予測のための方法及び試薬 | |
| Safarikova et al. | Mutational analysis of ACTN4, encoding [alpha]-actinin 4, in patients with focal segmental glomerulosclerosis using HRM method | |
| RU2020115869A (ru) | Варианты корнулина (crnn) и их применение | |
| CN103748470A (zh) | 一种预测治疗神经发育、神经学或神经精神病学疾病的临床益处的方法 | |
| Hebb et al. | Effects of IFN‐B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes | |
| US20150065380A1 (en) | Brain somatic mutations associated to epilepsy and uses thereof | |
| JP6942036B2 (ja) | 脳梗塞の発症リスクを高感度に検出する体液抗体バイオマーカー |